Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer

International Journal of Cancer

Volumn 119, Issue 7, 2006, Pages 1660-1665

  Zellweger, Tobias ^a   Benz, Gabriel ^a,b   Cathomas, Gieri ^b   Mihatsch, Michael J ^b   Sulser, Tullio ^a   Gasser, Thomas C ^a   Bubendorf, Lukas ^a,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Regional/University Department for Pathology   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bladder cancer; Bladder washings; Cytology; Fluorescence in situ hybridization; Recurrence

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; CANCER RECURRENCE; CANCER RISK; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CYSTOSCOPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 33747510349     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21704     Document Type: Article

References (21)

1. Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003;30:765-76.
2. Renshaw AA. Compassionate conservatism in urinary cytology. Diagn Cytopathol 2000;22:137-8.
3. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer 1999;87:118-28.
4. Quek ML, Sanderson K, Daneshmand S, Stein JP. New molecular markers for bladder cancer detection. Curr Opin Urol 2004;14:259-64.
5. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79-86.
6. Hailing KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O'Kane DJ et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000; 164:1768-75.
7. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, Procop GW, Jones JS, Ulchaker J, Zippe CD, Tubbs RR. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-5.
8. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-4.
9. Pycha A, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Vittadello F, Lusuardi L, Palermo S, Mian C. Intermediate-risk urothelial carcinoma: an unresolved problem? Urology 2004;63:472-5.
10. Esposti PL, Zajicek J. Grading of transitional cell neoplasms of the urinary bladder from smears of bladder washings. A critical review of 326 tumors. Acta Cytol 1972;16:529-37.
11. Bubendorf L, Grilli B. UroVysion multiprobe FISH in urinary cytology. Methods Mol Med 2004;97:117-31.
12. Sokolova IA, Hailing KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2:116-23.
13. Ye C, Liu J, Ren F, Okafo N. Design of experiment and data analysis by JMP (SAS institute) in analytical method validation. J Pharm Biomed Anal 2000;23:581-9.
14. Tsukamoto M, Matsuyama H, Oba K, Yoshihiro S, Takahashi M, Naito K. Numerical aberrations of chromosome 9 in bladder cancer. A possible prognostic marker for early tumor recurrence. Cancer Genet Cytogenet 2002;134:41-5.
15. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, Tammela TL. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41:284-9.
16. Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S, Obermann EC, Hammerschmied C, Wieland WF, Knuechel R, Hartmann A. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 2005;47:58-63.
17. Kline MJ, Wilkinson EJ, Askeland R, Given RW, Stephen C, Hendricks JB. DNA tetraploidy in Feulgen-stained bladder washings assessed by image cytometry. Anal Quant Cytol Histol 1995;17:129-34.
18. Bushman W, Goolsby C, Grayhack JT, Schaeffer AJ. Abnormal flow cytometry profiles in patients with interstitial cystitis. J Urol 1994;152:2262-6.
19. Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 1999; 155:105-13.
20. Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 2003;23:41-8.
21. Chang LL, Yeh WT, Yang SY, Wu WJ, Huang CH. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol 2003;170:595-600.